secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2024-07-26T23:59:59+00:00
Accession:  0001683168-24-005070
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma enters $5.2M ATM offering with A.G.P.; warrants repriced
-------------------------------------------------------------------

- Entered Sales Agreement with A.G.P. for at-the-market offering of up to $5.2M common stock; commission 3.0%.
- Net proceeds to be used for working capital and general corporate purposes.
- Waiver from Feb 2024 investor lifts restrictions on ATM; warrant exercise prices reduced.
- Effective Aug 1, 2024, exercise price of 587,028 Series A/B warrants lowered to Minimum Price.
- Additional 3,263,000 warrants repricing subject to shareholder approval; proxy statement due within 60 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824005070/0001683168-24-005070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824005070/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer